

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - **All Filers Are Required To Complete This Page**

1. Registrant Name:

PARRY ROMANI DECONCINI & SYMMS

2. Address:

517 C STREET, NE, WASHINGTON, DC 20002

3. Principal place of business (if different from line 2):

4. Contact Name: MICHELLE MAGOON

Telephone: 2025474000

E-mail (optional): mmagoon@lobbycongress.com

Senate ID #: 30792-2206

House ID #:

7. Client Name: Self

NOVARTIS CORP

TYPE OF REPORT

8. Year 2007 Midyear (January 1 - June 30): **OR** Year End (July 1 - December 31):

9. Check if this filing amends a previously filed version of this report:

10. Check if this is a Termination Report: => Termination Date: _____ 11. No Lobbying Activity:

INCOME OR EXPENSES

Complete Either Line 12 **OR** Line 13

12. Lobbying Firms

INCOME relating to lobbying activities for this reporting period was:

Less than \$10,000:

\$10,000 or more: => Income (nearest \$20,000): 120,000.00

Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).

13. Organizations

EXPENSES relating to lobbying activities for this reporting period were:

Less than \$10,000:

\$10,000 or more: => Expenses (nearest \$20,000): _____

14. Reporting Method.

Check box to indicate expense accounting method. See instructions for description of options.

- Method A.** Reporting amounts using LDA definitions only
 Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code
 Method C. Reporting amounts under section 162(e) of the Internal Revenue Code

LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: BUD (one per page)

16. Specific lobbying issues:

Funds for domestic vaccine supply, CDC, NIH and Vaccine Injury Compensation Fund. H.R. 3043: Making appropriations for the Departments of Labor, Health and Human Services, and Education, and related agencies for the fiscal year ending September 30, 2008, and for other purposes. Lobby for sufficient funding of the CDC and NIH.

17. House(s) of Congress and Federal agencies contacted:

Centers For Disease Control & Prevention (CDC)

HOUSE OF REPRESENTATIVES

Health & Human Services, Dept of (HHS)

Natl Institutes of Health (NIH)

SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: BAXTER, EDWARD

Covered Official Position (if applicable): N/A

Name: DECONCINI, DENNIS

Covered Official Position (if applicable): N/A

Name: HADDOW, JOHN

Covered Official Position (if applicable): N/A

Name: ROCK, JAMES

Covered Official Position (if applicable): N/A

Name: ROMANI, ROMANO

Covered Official Position (if applicable): N/A

Name: STROM, THADDEUS

Covered Official Position (if applicable): N/A

Name: SYMMS, STEVE

Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above.

Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: CPT (one per page)

16. Specific lobbying issues:

H.R. 1145, H.R. 1908: To amend Title 35, United States Code, relating to the procurement, enforcement, and validity of patents. Lobbied to protect intellectual property rights.

17. House(s) of Congress and Federal agencies contacted:

HOUSE OF REPRESENTATIVES
SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: BAXTER, EDWARD
Covered Official Position (if applicable): N/A
Name: DECONCINI, DENNIS
Covered Official Position (if applicable): N/A
Name: HADDOW, JOHN
Covered Official Position (if applicable): N/A
Name: ROCK, JAMES
Covered Official Position (if applicable): N/A
Name: ROMANI, ROMANO
Covered Official Position (if applicable): N/A
Name: STROM, THADDEUS
Covered Official Position (if applicable): N/A
Name: SYMMS, STEVE
Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above.

Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: HCR (one per page)

16. Specific lobbying issues:

Opposed efforts to amend the Federal Food, Drug and Cosmetic Act with respect to the sale of prescription drugs through the internet, and for other purposes. Lobbied to ensure that the Internet would not be used to import counterfeit and defective medical products. General matters related to vaccine industry stability, pandemic preparedness, avian influenza. Support enactment of S. 1695, the Biologics Price Competition and Innovation Act of 2007. Follow-on Biologics - H.R. 1038, Access to Life Saving Medicines Act and S. 1082, Prescription Drug User Fee Act.

17. House(s) of Congress and Federal agencies contacted:

Food & Drug Administration (FDA)
HOUSE OF REPRESENTATIVES
Health & Human Services, Dept of (HHS)
SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: BAXTER, EDWARD
Covered Official Position (if applicable): N/A
Name: DECONCINI, DENNIS
Covered Official Position (if applicable): N/A
Name: HADDOW, JOHN
Covered Official Position (if applicable): N/A
Name: ROCK, JAMES
Covered Official Position (if applicable): N/A
Name: ROMANI, ROMANO
Covered Official Position (if applicable): N/A
Name: STROM, THADDEUS
Covered Official Position (if applicable): N/A
Name: SYMMS, STEVE
Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above.

Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

Signature: ON FILE Date: Aug 14, 2007

Printed Name and Title: ROMANO ROMANI, PRESIDENT -